Abstract
A novel, highly stable, crystalline form of a formoterol derivative as a novel long-acting β2-agonist is claimed. Processes for its preparation, compositions containing the β2-agonist, and its use for the treatment of airway diseases are claimed. The claimed compound is believed to be 159797, currently in Phase II studies for the treatment of asthma and chronic obstructive pulmonary disease.